Abstract Clinical trials are reviewed, involving proteins and peptides derived from milk (predominantly bovine), with the exception of lactoferrin, which will be the subject of another article. The most explored milk fraction is α-lactalbumin (LA), which is often applied with glycomacropeptide (GMP) - a casein degradation product. These milk constituents are used in health-promoting infant and adult formulae as well as in a modified form (HAMLET) to treat cancer. Lactoperoxidase (LCP) is used as an additive to mouth hygiene products and as a salivary substitute. Casein derivatives are applied, in addition, in the dry mouth syndrome. On the other hand, casein hydrolysates, containing active tripeptides, found application in hypertension and in type 2 diabetes. Lysozyme is routinely used for food conservation and in pharmaceutical products. It was successfully used in premature infants with concomitant diseases to improve health parameters. When used as prophylaxis in patients with scheduled surgery, it significantly reduced the incidence of hepatitis resulting from blood transfusion. Lysozyme was also used in infected children as an antimicrobial agent showing synergistic effects in combination with different antibiotics. Proline-rich polypeptide (PRP) was introduced to therapy of Alzheimer's disease patients. The therapeutic value of PRP was proved in several clinical trials and supported by studies on its mechanism of action. Concentrated immunoglobulin preparations from colostrum and milk of hyperimmunized cows showed efficacy in prevention of infections by bacteria, viruses and protozoa. A nutrition formula with milk-derived TGF-β2 (Modulen IBD®) found application in treatment of pediatric Crohn's disease. In conclusion, the preparations containing milk-derived products are safe and effective measures in prevention and treatment of infections as well as autoimmune and neoplastic diseases.
AbstractList Clinical trials are reviewed, involving proteins and peptides derived from milk (predominantly bovine), with the exception of lactoferrin, which will be the subject of another article. The most explored milk fraction is α-lactalbumin (LA), which is often applied with glycomacropeptide (GMP) - a casein degradation product. These milk constituents are used in health-promoting infant and adult formulae as well as in a modified form (HAMLET) to treat cancer. Lactoperoxidase (LCP) is used as an additive to mouth hygiene products and as a salivary substitute. Casein derivatives are applied, in addition, in the dry mouth syndrome. On the other hand, casein hydrolysates, containing active tripeptides, found application in hypertension and in type 2 diabetes. Lysozyme is routinely used for food conservation and in pharmaceutical products. It was successfully used in premature infants with concomitant diseases to improve health parameters. When used as prophylaxis in patients with scheduled surgery, it significantly reduced the incidence of hepatitis resulting from blood transfusion. Lysozyme was also used in infected children as an antimicrobial agent showing synergistic effects in combination with different antibiotics. Proline-rich polypeptide (PRP) was introduced to therapy of Alzheimer's disease patients. The therapeutic value of PRP was proved in several clinical trials and supported by studies on its mechanism of action. Concentrated immunoglobulin preparations from colostrum and milk of hyperimmunized cows showed efficacy in prevention of infections by bacteria, viruses and protozoa. A nutrition formula with milk-derived TGF-β2 (Modulen IBD®) found application in treatment of pediatric Crohn's disease. In conclusion, the preparations containing milk-derived products are safe and effective measures in prevention and treatment of infections as well as autoimmune and neoplastic diseases.
Clinical trials are reviewed, involving proteins and peptides derived from milk (predominantly bovine), with the exception of lactoferrin, which will be the subject of another article. The most explored milk fraction is α-lactalbumin (LA), which is often applied with glycomacropeptide (GMP) - a casein degradation product. These milk constituents are used in health-promoting infant and adult formulae as well as in a modified form (HAMLET) to treat cancer. Lactoperoxidase (LCP) is used as an additive to mouth hygiene products and as a salivary substitute. Casein derivatives are applied, in addition, in the dry mouth syndrome. On the other hand, casein hydrolysates, containing active tripeptides, found application in hypertension and in type 2 diabetes. Lysozyme is routinely used for food conservation and in pharmaceutical products. It was successfully used in premature infants with concomitant diseases to improve health parameters. When used as prophylaxis in patients with scheduled surgery, it significantly reduced the incidence of hepatitis resulting from blood transfusion. Lysozyme was also used in infected children as an antimicrobial agent showing synergistic effects in combination with different antibiotics. Proline-rich polypeptide (PRP) was introduced to therapy of Alzheimer's disease patients. The therapeutic value of PRP was proved in several clinical trials and supported by studies on its mechanism of action. Concentrated immunoglobulin preparations from colostrum and milk of hyperimmunized cows showed efficacy in prevention of infections by bacteria, viruses and protozoa. A nutrition formula with milk-derived TGF-β2 (Modulen IBD®) found application in treatment of pediatric Crohn's disease. In conclusion, the preparations containing milk-derived products are safe and effective measures in prevention and treatment of infections as well as autoimmune and neoplastic diseases.Clinical trials are reviewed, involving proteins and peptides derived from milk (predominantly bovine), with the exception of lactoferrin, which will be the subject of another article. The most explored milk fraction is α-lactalbumin (LA), which is often applied with glycomacropeptide (GMP) - a casein degradation product. These milk constituents are used in health-promoting infant and adult formulae as well as in a modified form (HAMLET) to treat cancer. Lactoperoxidase (LCP) is used as an additive to mouth hygiene products and as a salivary substitute. Casein derivatives are applied, in addition, in the dry mouth syndrome. On the other hand, casein hydrolysates, containing active tripeptides, found application in hypertension and in type 2 diabetes. Lysozyme is routinely used for food conservation and in pharmaceutical products. It was successfully used in premature infants with concomitant diseases to improve health parameters. When used as prophylaxis in patients with scheduled surgery, it significantly reduced the incidence of hepatitis resulting from blood transfusion. Lysozyme was also used in infected children as an antimicrobial agent showing synergistic effects in combination with different antibiotics. Proline-rich polypeptide (PRP) was introduced to therapy of Alzheimer's disease patients. The therapeutic value of PRP was proved in several clinical trials and supported by studies on its mechanism of action. Concentrated immunoglobulin preparations from colostrum and milk of hyperimmunized cows showed efficacy in prevention of infections by bacteria, viruses and protozoa. A nutrition formula with milk-derived TGF-β2 (Modulen IBD®) found application in treatment of pediatric Crohn's disease. In conclusion, the preparations containing milk-derived products are safe and effective measures in prevention and treatment of infections as well as autoimmune and neoplastic diseases.
Author Zimecki, Michał
Artym, Jolanta
Author_xml – sequence: 1
  givenname: Jolanta
  surname: Artym
  fullname: Artym, Jolanta
– sequence: 2
  givenname: Michał
  surname: Zimecki
  fullname: Zimecki, Michał
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24018446$$D View this record in MEDLINE/PubMed
BookMark eNp1kE1LAzEQhoNUbK29e5I9etma2WSzyVGKVaHiRc9LNpmF6DZbk1Tw37ulrYjgXOaD5x1m3nMy8r1HQi6BzktB-Q1UrCiEYnOgAgQrT8hkN8p3s9GvekxmMb7RIbgSSsIZGRecguRcTEj55Lr33GJwn2izTegTOh8z7YcGN8lZjJnzmemcd0Z3WQpOd_GCnLZDwtkhT8nr8u5l8ZCvnu8fF7er3DAOKecVVA1rjFQNY4pLqwpZMFTWaBRYFRyQtZa1TQOVMSXoigK2tlGMVQVIy6bker93OOxjizHVaxcNdp322G9jDZyBgFJKGNCrA7pt1mjrTXBrHb7q46sDQPeACX2MAdsfBGi9M7Q-GlofDB0k4o_EuKST630K2nX_C78BPsZ2kA
CitedBy_id crossref_primary_10_1007_s12274_022_4385_4
crossref_primary_10_1016_j_ijbiomac_2020_07_224
crossref_primary_10_1155_2021_8822161
crossref_primary_10_1016_j_cofs_2017_03_003
crossref_primary_10_1111_jpn_13901
crossref_primary_10_1039_D0FO01447H
crossref_primary_10_1016_j_anaerobe_2017_05_001
crossref_primary_10_1016_j_arcped_2018_02_006
crossref_primary_10_3945_an_114_007690
crossref_primary_10_1080_10408398_2021_1895063
crossref_primary_10_17135_jdhs_2024_24_4_231
crossref_primary_10_1093_advances_nmaa120
crossref_primary_10_31067_acusaglik_1273983
crossref_primary_10_3390_biomedicines11041015
crossref_primary_10_2174_1567201819666220513085552
crossref_primary_10_1093_nutrit_nuaa045
crossref_primary_10_1155_2020_2894169
crossref_primary_10_3390_nu9010015
crossref_primary_10_3389_fphar_2021_767642
crossref_primary_10_1038_s41598_017_16962_6
crossref_primary_10_1007_s00005_016_0392_z
crossref_primary_10_3390_molecules27092941
crossref_primary_10_1590_fst_121122
crossref_primary_10_3390_nu10091332
crossref_primary_10_3389_fmicb_2022_1083432
crossref_primary_10_3390_app10207089
crossref_primary_10_1089_jmf_2019_0247
crossref_primary_10_1007_s11051_017_3782_1
crossref_primary_10_1016_j_fbio_2020_100771
crossref_primary_10_3390_life12040493
crossref_primary_10_1016_j_peptides_2015_08_009
crossref_primary_10_1080_20002297_2021_1879497
crossref_primary_10_1002_fsn3_2061
crossref_primary_10_2217_fvl_2020_0170
crossref_primary_10_3390_ijms241914730
crossref_primary_10_1007_s41061_017_0158_z
crossref_primary_10_3390_nu8080446
crossref_primary_10_1007_s10989_023_10541_2
crossref_primary_10_1038_s41390_020_0961_z
crossref_primary_10_1080_10408398_2023_2202254
crossref_primary_10_1016_j_jff_2015_06_021
crossref_primary_10_3390_pharmaceutics15041056
crossref_primary_10_3390_biomedicines11010114
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.5604/17322693.1061635
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1732-2693
EndPage 816
ExternalDocumentID 24018446
10_5604_17322693_1061635
Genre Journal Article
Review
GroupedDBID 2WC
3EA
5VS
AAYXX
ABDBF
ABMXE
ACUHS
AENEX
ALMA_UNASSIGNED_HOLDINGS
CITATION
DIK
EBD
EOJEC
ESX
F5P
GX1
KQ8
MK0
OBODZ
OK1
RNS
TUS
Y2W
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c341t-4717b3bc89b33948d92823e9dcae6e7241e3fd3fbb17cc51a701efdb9337218d3
ISSN 1732-2693
IngestDate Thu Jul 10 17:56:54 EDT 2025
Thu Apr 03 07:00:28 EDT 2025
Tue Jul 01 03:10:16 EDT 2025
Thu Apr 24 23:03:49 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c341t-4717b3bc89b33948d92823e9dcae6e7241e3fd3fbb17cc51a701efdb9337218d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink http://publisherspanel.com/icid/pdf/1061635
PMID 24018446
PQID 1431615881
PQPubID 23479
PageCount 17
ParticipantIDs proquest_miscellaneous_1431615881
pubmed_primary_24018446
crossref_primary_10_5604_17322693_1061635
crossref_citationtrail_10_5604_17322693_1061635
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-08-06
PublicationDateYYYYMMDD 2013-08-06
PublicationDate_xml – month: 08
  year: 2013
  text: 2013-08-06
  day: 06
PublicationDecade 2010
PublicationPlace Poland
PublicationPlace_xml – name: Poland
PublicationTitle Postȩpy higieny i medycyny doświadczalnej
PublicationTitleAlternate Postepy Hig Med Dosw (Online)
PublicationYear 2013
SSID ssj0000496981
Score 2.1720364
SecondaryResourceType review_article
Snippet Clinical trials are reviewed, involving proteins and peptides derived from milk (predominantly bovine), with the exception of lactoferrin, which will be the...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 800
SubjectTerms Adult
Alzheimer Disease - drug therapy
Animals
Anti-Bacterial Agents - pharmacology
Anti-Infective Agents - pharmacology
Antineoplastic Agents - therapeutic use
Autoimmune Diseases - drug therapy
Caseins - pharmacology
Caseins - therapeutic use
Cattle
Clinical Trials as Topic
Colostrum - chemistry
Diabetes Mellitus, Type 2 - drug therapy
Drug Synergism
Food Preservation - methods
Humans
Hypertension - drug therapy
Immunoglobulins - analysis
Immunoglobulins - therapeutic use
Infant
Infant Food
Infant, Premature, Diseases - drug therapy
Infection Control - methods
Lactalbumin - pharmacology
Lactoperoxidase - pharmacology
Milk - chemistry
Milk Proteins - analysis
Milk Proteins - pharmacology
Milk Proteins - therapeutic use
Neoplasms - drug therapy
Peptide Fragments - pharmacology
Xerostomia - drug therapy
Title Milk-derived proteins and peptides in clinical trials
URI https://www.ncbi.nlm.nih.gov/pubmed/24018446
https://www.proquest.com/docview/1431615881
Volume 67
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgkxAviDuDMQWJPqDJW1PnYj-2HdOEVJ42aeIl8pUFurRiGSj79Tu-pWUwBLxEURLbkT_n5Hy2z_kQeiszxUVGFS7ZCAgKMQxzrQWm8O9hqcnJ0AWFzT4WRyfZh9P8dKVP6KJLWrEnr34bV_I_qMI1wNVGyf4Dsn2lcAHOAV84AsJw_CuMZ_X8K1bQ0ndto_0XVrnS51xe2s0qym22WgU_OoWOi3V31Er1DqZ0MGbLbves_gzfebdb2wX3TnZwqhaDaT5gkx81V_KKzxv9ZTVC2s5HWAM5btreun-qz7X0WthuS76twAv_xMkFK_RA8TCkpvYGsSQjPCq8imG0mF5AI5g86jKN_mKKwZPK7KwAlLfF9yz1LHxmkjVklucOGnArgGlmN3Jiu79svHUXbY6ACYAp2xxPDiaH_UQaUJyC0dQvQdtW92-2aRM-h1p-9j5uoRTOtTh-iB4ETpCMPcCP0B3dPEb3ZmHXwxOUr-OcRJwTwDmJOCd1k0ScE4_zU3Ry-P54eoSD3AWW4Eq0GNyEUhAhKROEMPh-GNBhopmSXBe6BFdLE6OIESItpcxTXg5TbZRghACNp4o8QxvNotEvUJLC40LnMqdUZ9ykghtuFCPUOqjCpFtoP3ZDJUMueCtJMq-AE9o-rGIfVqEPt9C7vsTS50H5w7NvYs9WYKzsChRv9OLyAngmsQyDUniD577L-9oiRC9vvfMK3V-N0W200X671K_BJWzFThgU1_1MWbs
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Milk-derived+proteins+and+peptides+in+clinical+trials&rft.jtitle=Post%C8%A9py+higieny+i+medycyny+do%C5%9Bwiadczalnej&rft.au=Artym%2C+Jolanta&rft.au=Zimecki%2C+Micha%C5%82&rft.date=2013-08-06&rft.eissn=1732-2693&rft.volume=67&rft.spage=800&rft_id=info:doi/10.5604%2F17322693.1061635&rft_id=info%3Apmid%2F24018446&rft.externalDocID=24018446
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1732-2693&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1732-2693&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1732-2693&client=summon